ICUS Weekly News Monitor 1-30-2009

1.,  Jan 27, 2009,  BK Medical Introduces the Pro Focus Ultraview Ultrasound System  

Jan 27, 2009

BK Medical Introduces the Pro Focus Ultraview Ultrasound System  

BK Medical, a totally owned supplementary of Analogic Corporation, launches its new, full-featured ultrasound system, the Pro Focus UltraView, for the preoperative and urological ultrasound markets.

This high-performance ultrasound grouping uses BK Medical’s newborn IQPAC profession to wage payment images that attain a characteristic difference.

IQPAC profession combines BK Medical’s copyrighted Enhanced Tissue Definition and Angular Compound Imaging technologies to behave the ultrasound image. Enhanced Tissue Definition intensifies body borders by minimizing speckle, and Angular Compound Imaging uses images from individual angles to create a crack bilobed image. Together, these digit technologies enable IQPAC to wage significantly modern ikon quality. The UltraView grouping also features a 19″ high-definition guardian with ascendible ikon filler and a stamped keyboard for cushy cleaning.

“We are rattling chesty to promulgation our newborn top-of-the-line scanner. The UltraView strengthens our function as the mart cheater in special ultrasound,” affirms archangel Brock, President and CEO of BK Medical. “IQPAC puts our abdominal ikon calibre on par with the prizewinning in class. Furthermore, it reinforces our activity function within our status covering areas - preoperative and urological ultrasound imaging.”

The UltraView is a varied grouping that accommodates generalized clinical needs, patch ease substance a broad honor of specialization. It is harmonious with a super activity of special transducers, including high-performance lentiform and linelike array, biplane and triplane, and contrast-imaging?-enabled transducers for urological and preoperative applications. With its ambulatory and solidified design, the UltraView makes it doable to have ultrasound correct to the saucer of tending and to deal between departments. A user-friendly programme and ultimate keyboard attain the detector illogical and cushy to use.

In the USA, contrast-enhanced ultrasound has not been mart unwooded by the FDA, with the omission of exclusive superior cardiac imagery applications.

ICUS Weekly News Monitor 1-23-2009

1.  Cardiosource, American College of Cardiology,  Jan 21, 2009
Title: Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent (Multicenter Registry Results in 4,300,966 Consecutive Patients)
Topic: Noninvasive Cardiology
Author(s): Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M.

American College of Cardiology
Jan 21, 2009

Title: Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent (Multicenter Registry Results in 4,300,966 Consecutive Patients)
Topic: Noninvasive Cardiology
Author(s): Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M.
Study Question: What is the short-term mortality for hospitalized patients undergoing echocardiography with and without perflutren lipid microsphere (PLM) contrast agent?
Methods: This was a retrospective review of 4,300,966 consecutive patients identified in the Premier Perspective Database (hospital-based, service-level, comparative database) undergoing clinically indicated echocardiography between January 1, 2002 and October 31, 2007. Patient demographics, illness severity, risk of mortality, and 1-day mortality were collected. Controlling for demographic and clinical covariate differences, the 1-day mortality was compared between patients who did and did not receive PLM at the time of echocardiography.
Results: During the study period, 4,300,966 patients underwent echocardiography without (n = 4,242,712) and with PLM (n = 58,254). The 1-day mortality was 1.08% and 1.06%, respectively. Multivariate logistic regression revealed that patients receiving PLM contrast agent were 24% less likely to die. Overall, the PLM contrast agent group was older, sicker, more likely to die, and more likely to have a Food and Drug Administration (FDA) defined (2007) contraindication to ultrasound contrast agent use.
Conclusions: There was no significant difference in crude 1-day mortality between patients who did and did not receive PLM contrast agent while undergoing echocardiography.
Perspective: The new warnings and contraindications for ultrasound contrast agent issued in October of 2007 were based on a relatively small number of temporally related deaths. Following further investigation, these warnings were relaxed in July of 2008; however, concern remains regarding the use of these agents in critically ill patients. This study supports the findings of a recent single institution study, which did not demonstrate any mortality difference with the use of ultrasound contrast agent. Based on the unstable cardiopulmonary conditions, as defined by the FDA in 2007, more patients in the PLM group for this study had one of these contraindications. However, the mortality rate was equal between groups and the risk of mortality, when covariates were controlled for, was 24% lower in the PLM group. Despite the large sample size, this study is limited by the relatively low usage rate of ultrasound contrast agent. However, the compelling findings of this study warrant further assessment by clinicians and federal agencies regarding the indications for clinical use and “box label” warnings for ultrasound contrast agent.  Jennifer C. Hirsch, M.D., F.A.C.C.

ICUS Weekly News Monitor 1-16-2009

1.  MarketWatch,  Jan. 14, 2009,    Learn about the Biologic Imaging Reagents: Technologies and Global Markets

2.  Globe Newswire,  Jan 13, 2009,    Vital Images and Toshiba Sign Co-development Agreement; New Agreement Expands Relationship With Toshiba; Supports Collaboration On Technology Advancement

3.,  Jan 12, 2009,    HM Pharma Consultancy Publishes New Market Report on Molecular Imaging

Jan. 14, 2009

Learn about the Biologic Imaging Reagents: Technologies and Global Markets

NEW YORK, Jan 14, 2009 (BUSINESS WIRE) -- announces that a new market research report related to the Diagnostic equipment industry is available in its catalogue.
Biologic Imaging Reagents: Technologies and Global Markets
BCC's goal for this study is to determine the global market and future demand growth for biologic imaging reagents over a five-year period from 2008 to 2013. Our particular interest is to characterize and quantify the biologic imaging reagents market potential by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biologic imaging reagents such as quantum dots, nanoparticles, fluorescent proteins and supermolecules.
Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; fullerene and dendrimer supermolecules; magnetic resonance imaging; ultrasound and x-ray contrast reagents; and imaging radiopharmaceuticals.
Our key objective is to present a comprehensive discussion of where the state-of-the-art is in biologic imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biologic imaging reagents. The study will benefit reagent and instrument manufacturers; users of biologic imaging reagents; medical instrument companies; life sciences tools companies; diagnostic and drug manufacturers; biotechnology companies; and developers of nanotechnologies.
Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as x-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biologic imaging reagents play a critical role in this medical revolution.
At the same time, tremendous advances in genomics, proteomics and cellular analysis are assisted by imaging technologies including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing, and PCR relies on sensitive biologic fluorescent imaging reagents.
Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biologic imaging reagents.
Given these market and technology dynamics, it is especially timely to examine the biologic imaging reagents market.
We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments including life science research tools, drug discovery and development, and diagnostics. We present the various imaging reagent technologies, including fluorescent probes and dyes; nanomaterials; fluorescent proteins; supermolecules; contrast reagents, and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential and product sales forecasts for the period 2008 through 2013. We project the future use of biologic imaging reagents in the main end user segments and by technology.
This study will be of particular interest to life science research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction (PCR), molecular diagnostics assays, fluorescence in-situ hybridization (FISH), fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.

Globe Newswire
Jan 13, 2009

Vital Images and Toshiba Sign Co-development Agreement
New Agreement Expands Relationship With Toshiba; Supports Collaboration On Technology Advancement

MINNEAPOLIS, Jan. 13, 2009 (GLOBE NEWSWIRE) -- Vital Images, Inc. (Nasdaq:VTAL), a leading provider of advanced visualization and analysis software, and Toshiba Medical Systems Corporation (Toshiba), have signed a co-development and collaboration agreement in which they will enter into a mutual license of intellectual property and will jointly invest to develop and deliver innovative technology advancements for Toshiba's modalities, including the Aquilion(tm) ONE CT scanner, and Vital Images' advanced visualization software solutions.

The companies recently announced the renewal of their distribution agreement, which has been extended until 2013. The lengthened term of the new contract, complemented by the co-development and collaboration agreement, enables the companies to jointly drive new technology and closely collaborate in developing and launching industry-leading advanced visualization solutions for medical imaging.

"We have had a close working relationship with Toshiba on Vitrea fX and Aquilion ONE for the past few years," said Vikram Simha, chief technology officer at Vital Images. "However, this agreement establishes a new development framework enabling our companies to more rapidly create innovations, intellectual property and next-generation technologies for all Toshiba modalities."

"Toshiba believes that the new agreements recently signed with Vital Images for distribution and development will continue to enhance and extend our strategic partnership with Vital Images. These agreements will help us achieve our joint goal to deliver unique clinical capabilities leveraging industry-leading technology from both Toshiba and Vital Images," said Yasuo Nobuta, general manager of CT Division, Toshiba Medical Systems Corp. "Toshiba looks to strengthen its collaboration with Vital Images to develop industry-leading solutions."

About the Aquilion One and Vitrea fX

Toshiba's Aquilion ONE is the first dynamic volume CT scanner. This system revolutionizes patient care by non-invasively providing structural and function information key to diagnostic decision and reducing diagnostic time for life-threatening conditions, such as stroke and heart disease, from days and hours to mere minutes. Unlike any other CT system, the Aquilion ONE can scan an entire organ in one rotation, dramatically cutting the exam time as well as radiation and contrast doses. Each Aquilion ONE ships with a Vitrea fX solution -- designed in collaboration with Toshiba for the Aquilion ONE. Vitrea fX has both FDA marketing clearance and CE Mark approval. Aquilion ONE is a trademark of Toshiba Medical Systems Corporation.

About Toshiba Medical Systems Corporation

Toshiba Medical Systems Corporation is an independent group company of Toshiba Corporation. The company is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT scanners, X-ray, Ultrasound, Nuclear Medicine, MRI equipment, and information systems for medical institutions. Toshiba Corporation is a leader in information and communications systems, electronic components, consumer products and power systems. Toshiba Corporation has approximately 198,000 employees and annual sales of $77 billion. For more information, visit,

About Vital Images, Inc.

Vital Images, Inc., established in 1988 and headquartered in Minneapolis, is a leading provider of advanced visualization software solutions. The company's technology gives radiologists, cardiologists, oncologists and other medical specialists, time-saving productivity and communications tools that can be accessed throughout the enterprise and via the Web for easy use in the day-to-day practice of medicine. Vital Images also has offices in Europe and Asia. For more information, visit

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that Act. These statements involve risks and uncertainties which could cause results to differ materially from those projected, including but not limited to dependence on market growth, challenges associated with international expansion, the ability to predict product, customer and geographic sales mix, regulatory approvals, the timely introduction, availability and acceptance of new products, the impact of competitive products and pricing, dependence on major customers, the ability to successfully manage operating costs, fluctuations in quarterly results, approval of products for reimbursement and the level of reimbursement, general economic conditions and other factors detailed from time to time in Vital Images' SEC reports, including its annual report on Form 10-K for the year ended December 31, 2007. Vital Images encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and the company undertakes no obligation to update them to reflect subsequent events or circumstances.

CONTACT:  Vital Images, Inc.
          Michael H. Carrel, President and Chief Executive Officer
          (952) 487-9500

Jan 12, 2009

HM Pharma Consultancy Publishes New Market Report on Molecular Imaging

Vienna, Austria - Insight Pharma Reports has published HM Pharma Consultancy's new report on molecular imaging, the enabling integrative technology that is constantly finding new applications in the life science industry.

Molecular imaging has proved extremely useful across the entire drug development pipeline, from drug target discovery to routine clinical diagnostics. The technologies employed range from optical proximity assays, which visualize the binding of ligands to receptors in living cells to tomography of patients' bodies based on positrons emitted by radioactive tracers.

"A most impressive cutting-edge technology spectrum is being put to work to visualize molecular events of biological relevance in basic biology, transitional research, and advanced routine diagnostics," said report author Hermann AM Mucke. "Molecular imaging can add incredible value to almost any cellular, animal and human research that is conducted today. This is true for academic as well as pharmaceutical investigations."

As a result of this diversity in several dimensions, there is no single 'molecular imaging market.' Rather, there are several partially connected markets: for optical cellular imaging in R&D, consisting of a market for advanced microscopes and a market for optical probes; for near-infrared imaging of laboratory animals, divided into an equipment and a probe market; for tomographic scanners (based on X-rays, magnetic resonance, or nuclear isotopes, alone or in combination, and in different sizes for laboratory animals and humans); for ultrasound imaging equipment; for X-ray, magnetic resonance, and ultrasound contrast agents which concern molecularly or metabolically differentiating agents; and for radioactive isotopic probes, assisted by a secondary market for the logistics of those probes that decay particularly rapidly but can only be manufactured in cyclotrons. An overarching market of computer systems and software takes care of the processing, analysis, and storage of the captured images.

HM Pharma Consultancy's report investigates all these aspects, along with the technology that constitutes their underpinning, and adds additional information from a survey of molecular imaging researchers. The report, titled Biomedical Imaging: From Drug Target Discovery to Medical Diagnostics is available from Insight Pharma Reports, a division of the Cambridge Healthtech Institute.

For details on buying the report, please visit Insight Pharma Reports' website, or call Rose LaRaia at +1 781 972 5444.

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:






Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News